Ra Capital Management, L.P. Acquires 320,913 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Ra Capital Management, L.P. purchased 320,913 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $0.86 per share, with a total value of $275,985.18. Following the completion of the transaction, the director now owns 6,021,969 shares in the company, valued at approximately $5,178,893.34. This trade represents a 5.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 14th, Ra Capital Management, L.P. bought 162,539 shares of Werewolf Therapeutics stock. The stock was bought at an average price of $0.98 per share, for a total transaction of $159,288.22.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $1.11 on Friday. The stock has a 50 day moving average of $0.93 and a 200 day moving average of $1.39. The company has a market capitalization of $49.81 million, a price-to-earnings ratio of -0.73 and a beta of 0.48. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $5.73. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 8th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. As a group, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOWL. Wedbush lowered their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research report on Friday, May 9th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, March 12th.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Barclays PLC raised its stake in shares of Werewolf Therapeutics by 130.1% during the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after purchasing an additional 30,990 shares during the period. Bank of New York Mellon Corp raised its position in shares of Werewolf Therapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock valued at $106,000 after buying an additional 13,372 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Werewolf Therapeutics by 372.4% in the 4th quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after purchasing an additional 49,608 shares in the last quarter. Geode Capital Management LLC grew its position in Werewolf Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after acquiring an additional 16,569 shares during the last quarter. Finally, Levin Capital Strategies L.P. purchased a new position in Werewolf Therapeutics in the 4th quarter worth $74,000. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.